LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Filter results: >>>>
Cell Small Molecule Small Mol Concentration Small Mol Conc Unit LJP Library Plate Replicate Assay Well Timepoint Timepoint Unit Total Cell Count Before Treatment Total Cell Count After Treatment Total Control Cell Count Relative Cell Count Relative Growth Rate After Treatment
SK-BR-3 Dasatinib
10.0
uM
LJP5
3
D01
72
hr
1401 2000 4223 0.4736 0.2121
SK-BR-3 Nilotinib
10.0
uM
LJP5
1
N13
72
hr
1401 2115 4223 0.5008 0.2529
SK-BR-3 QL-XII-47
10.0
uM
LJP6
3
O19
72
hr
1401 1192 4223 0.2823 -0.0743
SK-BR-3 Ruxolitinib
10.0
uM
LJP5
3
O13
72
hr
1401 3813 4223 0.9029 0.8547
SK-BR-3 OSI-027
0.04
uM
LJP6
3
E12
72
hr
1401 3026 4223 0.7165 0.5757
SK-BR-3 JNK-9L
0.12
uM
LJP6
2
K23
72
hr
1401 3306 4223 0.7828 0.6750
SK-BR-3 Seliciclib
0.04
uM
LJP5
3
J06
72
hr
1401 4492 4223 1.0637 1.0953
SK-BR-3 Afatinib
0.12
uM
LJP6
2
G23
72
hr
1401 1378 4223 0.3263 -0.0083
SK-BR-3 Dasatinib
0.37
uM
LJP5
2
D04
72
hr
1401 4491 4223 1.0634 1.0950
SK-BR-3 Geldanamycin
1.11
uM
LJP6
3
O03
72
hr
1401 1331 4223 0.3152 -0.0250
SK-BR-3 Lapatinib
3.33
uM
LJP6
1
M20
72
hr
1401 1560 4223 0.3694 0.0562
SK-BR-3 Foretinib
10.0
uM
LJP5
1
H07
72
hr
1401 1406 4223 0.3329 0.0016
SK-BR-3 SNS-032
0.04
uM
LJP6
1
H18
72
hr
1401 2692 4223 0.6375 0.4574
SK-BR-3 XMD11-85h
0.04
uM
LJP6
1
P24
72
hr
1401 3393 4223 0.8034 0.7058
SK-BR-3 Ruxolitinib
0.04
uM
LJP5
1
O18
72
hr
1401 3818 4223 0.9041 0.8564
SK-BR-3 Momelotinib
0.37
uM
LJP5
3
P10
72
hr
1401 4150 4223 0.9827 0.9741
SK-BR-3 JW-7-24-1
3.33
uM
LJP6
3
B20
72
hr
1401 2240 4223 0.5304 0.2972
SK-BR-3 PHA-793887
10.0
uM
LJP6
3
E19
72
hr
1401 864 4223 0.2046 -0.1905
SK-BR-3 Withaferin A
0.04
uM
LJP5
2
G18
72
hr
1401 4109 4223 0.9730 0.9596
SK-BR-3 JW-7-24-1
3.33
uM
LJP6
1
B20
72
hr
1401 2168 4223 0.5134 0.2717